Broadwood Partners, L.P. filed a Statement of Changes in Beneficial Ownership with the SEC on November 19, 2026, disclosing a purchase of common stock in Insight Molecular Diagnostics Inc. on November 17, 2026.
Key Highlights
- Shares acquired: Broadwood Partners, L.P. purchased 3,428,571 shares of Common Stock, no par value, on November 17, 2026.
- Purchase price: The shares were acquired at $1.75 per share, for a total purchase price of $5,999,999.25, according to the filing.
- Transaction type: The purchase was made in an underwritten public offering directly from the issuer, Insight Molecular Diagnostics Inc.
- Post-transaction ownership: Following the transaction, Broadwood Partners directly holds 16,113,455 shares of Common Stock.
- Warrants held: The filing also reports 150,093 warrants to purchase Common Stock, exercisable at $30.6, expiring April 19, 2027, held both directly and indirectly.
- Reporting persons: The filing is made jointly by Broadwood Partners, L.P., Broadwood Capital, Inc. (as General Partner), and Neal C. Bradsher (as President of Broadwood Capital).
Broadwood Partners Discloses Large Stock Purchase in Insight Molecular Diagnostics Underwritten Offering
According to the filing, Broadwood Partners, L.P. acquired 3,428,571 shares of Common Stock, no par value, of Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) on November 17, 2026, through an underwritten public offering at $1.75 per share. The total purchase price was reported as $5,999,999.25. Following this transaction, Broadwood Partners directly holds 16,113,455 shares of Common Stock in the issuer, the filing states.
The filing identifies three reporting persons: Broadwood Partners, L.P., Broadwood Capital, Inc., and Neal C. Bradsher. Broadwood Capital, Inc. serves as General Partner of Broadwood Partners, and Neal C. Bradsher is President of Broadwood Capital. Each reporting person is identified as a 10% owner of Insight Molecular Diagnostics Inc. The filing notes that "each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein," and states that the report "shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."
In addition to the common stock position, the filing discloses that Broadwood Partners holds warrants to purchase 150,093 shares of Common Stock, with a conversion or exercise price of $30.6, currently exercisable, and expiring April 19, 2027. These warrants are reported both directly by Broadwood Partners and indirectly. Separately, the filing discloses that Neal C. Bradsher directly holds 157 shares of Common Stock in a personal capacity, distinct from the shares held through Broadwood Partners.
What Was Disclosed
The filing reports a purchase of 3,428,571 shares of Insight Molecular Diagnostics Inc. common stock by Broadwood Partners, L.P. at $1.75 per share in an underwritten public offering on November 17, 2026, bringing the firm's direct beneficial ownership to 16,113,455 shares. Existing warrant holdings and a personal share position for Neal C. Bradsher were also disclosed.




Please wait processing your request...